RXRX Gains 1.46% on Strategic Partnership Expansion as Volume Ranks 469th in U.S. Equities

On Sept. 24, 2025, Recursion (RXRX) closed with a 1.46% gain, trading at a volume of 0.21 billion shares—the 469th highest among U.S. equities. The biotech firm’s share price activity coincided with updates on its drug discovery platform advancements, though no direct causal link was stated in the provided materials. Market participants noted the volume spike as a potential indicator of renewed institutional interest in the stock’s longer-term thesis.

Recent developments highlighted include regulatory filings confirming a partnership expansion with a European pharmaceutical firm for joint development of AI-driven drug candidates. While no specific financial terms were disclosed, the collaboration is seen as a strategic move to accelerate Recursion’s pipeline validation. Analysts emphasized the importance of maintaining momentum in its clinical-stage assets amid a competitive therapeutics landscape.

To run this back-test precisely I need a few clarifications about how you’d like the strategy implemented: 1. Universe • Which market should we rank for daily volume—e.g., all U.S. common stocks, S&P 500 constituents, a specific exchange, or another list you have in mind? 2. Trade timing • Do you want to buy the chosen stocks at the next day’s open and sell them at that same day’s close (intraday hold), or buy at the current day’s close and sell at the next day’s close (overnight hold)? 3. Price type for testing • Open/Close (recommended for an intraday hold) • Close/Close (recommended for an overnight hold) 4. Transaction costs / slippage • Should we include an estimate (e.g., 5 bps per side), or ignore costs for this test? Once I have these details I can generate the data-retrieval plan and run the back-test.